TP53 and neoplasm: Going forward, one of the most promising approaches for targeting mutant proteins such as mutant p53 is likely to be the use of bispecific T-cell receptor mimic antibodies, i.e., antibodies in which one end binds to a mutant epitope on a tumor cell and the other end to a T-cell.